Flibanserin (Addyi®)

In 2015, the U.S. Food and Drug Administration (FDA) approved flibanserin (brand name Addyi®, pronounced add-ee) for the treatment of “acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.” Note that there are four parts to the FDA approval of flibanserin: diagnosis of HSDD, acquired, generalized, and premenopausal women only. Below, I’ll explain each…